VERAXA Biotech enters co-discovery alliance with OmniAb for a novel bispecific antibody drug conjugate program

CAR-T Digest - August 2020

05 May 2025: VERAXA Biotech enters co-discovery alliance with OmniAb for a novel bispecific antibody drug conjugate program

VERAXA Biotech has entered into a co-discovery alliance with OmniAb to develop a novel bispecific antibody drug conjugate (bsADC) targeting solid tumors
The collaboration combines OmniAb’s transgenic antibody discovery platform with VERAXA’s proprietary ADC linker and conjugation technology to create next-generation therapeutics
The bsADC program will focus on two cancer-related targets, with VERAXA responsible for establishing the lead candidate and conducting preclinical validation
The resulting therapeutic program will be jointly owned, with both companies sharing potential future revenues from development, licensing, and commercialization
This marks VERAXA’s second major strategic partnership within six months, and it follows the company’s announced plan to go public via a merger with Voyager Acquisition Corp